en بیوشیمی Biochemistry مقالات اصلی Original Article <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt">Background:</span></span></span></span></i></b><b><i> </i></b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt">Type 2 diabetes mellitus (T2DM) poses a significant public health challenge due to its high prevalence. Diabetic nephropathy (DN) is one of the most severe complications associated with T2DM. Early prediction of DN in patients with T2DM can significantly aid in managing this disease.</span></span></span></span> <span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt">This study takes an approach by investigating the potential role of melatonin and thyroid hormone levels as predictive biomarkers for the progression of diabetic nephropathy in individuals diagnosed with type 2 diabetes mellitus.</span></span></span></span></span></span></span></span></span><br> <br> <span style="font-size:10pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt">Methods:</span></span></span></span></i></b><b> </b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt">Our cross-sectional study involved 120 male participants, divided into two groups: 60 patients with T2DM and 60 with DN. The Cobas technique was used to measure serum thyroid hormone levels and quantified melatonin levels using an enzyme-linked immunosorbent assay (ELISA). A receiver utilizing characteristic (ROC) curve analysis to evaluate the predictive value of serum melatonin for DN was performed.</span></span></span></span></span></span></span></span></span><br> <br> <span style="font-size:10pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt">Results:</span></span></span></span></i></b><b> </b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt">No notable disparities in thyroid function tests were observed between diabetic patients with and without DN. However, the average serum melatonin quantity in patients with DN. (177.25 &plusmn; 60.48 pg/mL) was drastically lower in those with T2DM without DN (199.9 &plusmn; 55.16 pg/mL). The sensitivity and specificity of melatonin in predicting DN were 78% and 76%, respectively, with an optimal cut-off value of 178 pg/mL.</span></span></span></span></span></span></span></span></span><br> <br> <span style="font-size:10pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt">Conclusions:</span></span></span></span></i></b><b> </b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt">Serum melatonin levels exhibited a notable reduction. among individuals who were diabetic with DN, suggesting its potential utility as an additional predictive marker for developing DN in patients with T2DM.</span></span></span></span></span></span></span></span></span></div> Diabetes Mellitus, Diabetic Nephropathy, Melatonin, Thyroid Activity Tests. 341 348 http://rbmb.net/browse.php?a_code=A-10-1493-1&slc_lang=en&sid=1 Refaa Burhan Altemimi 100319475328460020692 100319475328460020692 No Department of anesthesia techniques, College of Health and Medical Technology, Middle Technical university, Baghdad, Iraq. Nabaa Nabil Ibrahim 100319475328460020693 100319475328460020693 No Department of Pharmacognosy and Medicinal Plants, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq. Lara Ali Nazar 100319475328460020694 100319475328460020694 No Department of Chemistry, College of Sciences, Mustansiriyah University, Baghdad, Iraq. Hiba Ali Hasan 100319475328460020695 100319475328460020695 No Department of Pharmacognosy and Medicinal Plants, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq. Mastafa Heilo Al-Musawi mustafa.h.j@uomustansiriyah.edu.iq. 100319475328460020696 100319475328460020696 Yes Department of Clinical Laboratory Sciences, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq. Fatemeh Mortazavi Moghadam 100319475328460020697 100319475328460020697 No Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran.